U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515391) titled 'Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery' on Dec. 11, 2019.
Brief Summary: This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
Study Start Date: Oct. 22, 2019
Study Type: INTERVENTIONAL
Condition:
Bariatric Surgery Candidate
Type2 Diabetes
Intervention:
DRUG: Dapagliflozin 10 MG
Dapagliflozin 10 mg drug will be administered in both arms fo...